CD74 Polypeptides for MIF Binding Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic autoimmune diseases like multiple sclerosis and experimental autoimmune encephalomyelitis, such as RTL1000 and DRα1-MOG-35-55, require HLA subtyping and have limitations in effectively inhibiting Macrophage Migration Inhibitory Factor (MIF) binding and downstream signaling.
Innovation Solution
Development of polypeptides derived from CD74 that compete with recombinant T cell receptor ligands and partial MHC molecules for binding to MIF, including specific sequences like SEQ ID NO: 1, 2, 3, and 4, which can be used in compositions with or without linkers, to inhibit MIF binding without the need for HLA subtyping.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments like RTL1000 and DRα1-MOG-35-55 are used to inhibit MIF binding, then MIF binding inhibition is achieved, but HLA subtyping is required and therapeutic effectiveness is limited
Solution Approach 1:
The patent extracts the essential MIF-binding functional domain from the full CD74 receptor, creating simplified polypeptide fragments (such as amino acids 116-193 or 140-193 of CD74) that retain MIF binding capability without requiring the complete receptor structure or HLA subtyping procedures. This extraction eliminates the complexity of HLA subtyping while preserving the therapeutic effect of MIF binding inhibition.
Solution Approach 2:
The patent creates simplified copies or fragments of the CD74 receptor that replicate the essential MIF-binding function. These polypeptide copies (e.g., amino acid sequences 116-193, 140-193, or 173-193 of human CD74) mimic the binding interface of the full receptor, providing therapeutic effectiveness without requiring the complex HLA subtyping needed for full MHC molecules like DRα1-MOG-35-55.
2Reliability
If full CD74 receptor or complete MHC molecules are used for MIF binding inhibition, then binding inhibition is achieved, but treatment complexity and patient selection requirements increase
Solution Approach 1:
The patent segments the full CD74 receptor into smaller functional polypeptide fragments that contain the essential MIF-binding domain. Examples include amino acids 116-193, 140-193, or 173-193 of human CD74, which are smaller versions of the full receptor (amino acids 1-667) but retain MIF binding capability. This segmentation simplifies the treatment by eliminating the need for complex HLA subtyping while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polypeptides effectively block MIF binding and downstream signaling, reducing inflammation and autoimmune responses, as demonstrated by their ability to inhibit CD74 binding to MIF and other ligands, potentially offering a broader therapeutic effect than existing treatments.
Implementation Method 1
polypeptides derived from CD74 that can compete with recombinant T cell receptor ligands (RTLs) such as RTL1000... for binding of the CD74 ligand macrophage migration inhibitory factor (MIF)
Data Source
AI summary
Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.